floxabactin vet 15 mg tabletti
le vet. b.v. - enrofloxacin - tabletti - 15 mg - enrofloksasiini
floxabactin vet 50 mg tabletti
le vet. b.v. - enrofloxacin - tabletti - 50 mg - enrofloksasiini
floxabactin vet 150 mg tabletti
le vet. b.v. - enrofloxacin - tabletti - 150 mg - enrofloksasiini
sedastart vet 1 mg/ml injektioneste, liuos
le vet. b.v. - medetomidine hydrochloride - injektioneste, liuos - 1 mg/ml - medetomidiini
sedastop vet 5 mg/ml injektioneste, liuos
le vet. b.v. - atipamezole hydrochloride - injektioneste, liuos - 5 mg/ml - atipametsoli
detonervin vet 10 mg/ml injektioneste, liuos
le vet. b.v. - detomidine hydrochloride - injektioneste, liuos - 10 mg/ml - detomidiini
euthasol vet 400 mg/ml injektioneste, liuos
le vet. b.v. - pentobarbital sodium - injektioneste, liuos - 400 mg/ml - pentobarbitaali
nerfasin vet 20 mg/ml injektioneste, liuos
le vet. b.v. - xylazine hydrochloride - injektioneste, liuos - 20 mg/ml - ksylatsiini
nerfasin vet 100 mg/ml injektioneste, liuos
le vet. b.v. - xylazine hydrochloride - injektioneste, liuos - 100 mg/ml - ksylatsiini
cancidas (previously caspofungin msd)
merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimykoottiset aineet systeemiseen käyttöön - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.